Skip to content
10-Q

Quarterly Report

TEVA PHARMACEUTICAL INDUSTRIES LIMITED TEVA TEVJF

0001193125-25-114889

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Mar 31, 2025 1.15B sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.7B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $3.3B
Stockholders Equity Q1 2025 · Mar 31, 2025 $6.26B
Stockholders Equity Q1 2025 · Dec 31, 2024 $5.37B
Current Liabilities Q1 2025 · Mar 31, 2025 $11.16B
Current Liabilities Q1 2025 · Dec 31, 2024 $12.8B
Total Liabilities Q1 2025 · Mar 31, 2025 $32.15B
Total Liabilities Q1 2025 · Dec 31, 2024 $33.61B
Current Assets Q1 2025 · Mar 31, 2025 $11.53B
Current Assets Q1 2025 · Dec 31, 2024 $12.55B
Total Assets Q1 2025 · Mar 31, 2025 $38.42B
Total Assets Q1 2025 · Dec 31, 2024 $39.33B
Shares Diluted Q1 2025 · Mar 31, 2024 1.12B sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$124M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.12
Eps Basic Q1 2025 · Mar 31, 2024 −$0.12
Sga Expense Q1 2025 · Mar 31, 2024 $278M
Net Income Q1 2025 · Mar 31, 2024 −$139M
Operating Income Q1 2025 · Mar 31, 2024 −$218M
Gross Profit Q1 2025 · Mar 31, 2024 $1.77B
Cost Of Revenue Q1 2025 · Mar 31, 2024 $2.05B
Revenue Q1 2025 · Mar 31, 2024 $3.82B